Cosentyx Injection
Product Images NDC 0078-0639

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 48 technical images submitted to the FDA as part of the official labeling for Cosentyx (NDC 0078-0639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel Ndc 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/ml 1 Prefilled Syringe Attention: Dispense With Enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution (Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS)

Principal Display Panel Ndc 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/ml 1 Prefilled Syringe Attention: Dispense With Enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution (Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS)
This is a description of Cosentyx medication, which is used for subcutaneous injection. The medication comes in the form of a single-dose prefilled syringe containing 150 mg of secukinumab, and should be stored in a refrigerator at a temperature of 2-8°C (36-46°F). The medication can be stored at room temperature for up to 0-30°C (86°F) for a maximum of 4 days, after which it should be discarded. The medication guide enclosed should be followed while dispensing the medication. The medication may contain Latex which may cause an allergic reaction. For more information, visit the Cosentyx official website or call 1-835 NOW-1IOVA (-888-860-6622).*
FDA Label Image

Figure A (Cosentyx 02)

Figure A (Cosentyx 02)
FDA Label Image

Figure B (Cosentyx 03)

Figure B (Cosentyx 03)
FDA Label Image

Figure C (Cosentyx 04)

Figure C (Cosentyx 04)
FDA Label Image

Figure D (Cosentyx 05)

Figure D (Cosentyx 05)
FDA Label Image

Figure E (Cosentyx 06)

Figure E (Cosentyx 06)
FDA Label Image

Figure F (Cosentyx 07)

Figure F (Cosentyx 07)
FDA Label Image

Cosentyx Prefilled Syringe Parts (see Figure A): (Cosentyx 08)

Cosentyx Prefilled Syringe Parts (see Figure A): (Cosentyx 08)
This appears to be a description of a syringe with various features such as finger grips, a needle cap, a viewing window, label & expiration date, guard wings and plunger head. It is likely a medical device used for injecting medication or other substances.*
FDA Label Image

Figure B (Cosentyx 09)

Figure B (Cosentyx 09)
FDA Label Image

Figure C (Cosentyx 10)

Figure C (Cosentyx 10)
FDA Label Image

Figure D (Cosentyx 11)

Figure D (Cosentyx 11)
FDA Label Image

Figure E (Cosentyx 12)

Figure E (Cosentyx 12)
FDA Label Image

Figure F (Cosentyx 13)

Figure F (Cosentyx 13)
FDA Label Image

Figure G (Cosentyx 14)

Figure G (Cosentyx 14)
FDA Label Image

Figure H (Cosentyx 15)

Figure H (Cosentyx 15)
FDA Label Image

Figure I (Cosentyx 16)

Figure I (Cosentyx 16)
FDA Label Image

Figure J (Cosentyx 17)

Figure J (Cosentyx 17)
FDA Label Image

Figure A (Cosentyx 18)

Figure A (Cosentyx 18)
This text describes the features of a needle that includes a needle guard, cap, viewing window, and internal needle cover.*
FDA Label Image

Figure B (Cosentyx 19)

Figure B (Cosentyx 19)
FDA Label Image

Figure C (Cosentyx 20)

Figure C (Cosentyx 20)
FDA Label Image

Figure D (Cosentyx 21)

Figure D (Cosentyx 21)
This text simply states "Viewing window" and does not provide enough context to generate a useful description.*
FDA Label Image

Figure E (Cosentyx 22)

Figure E (Cosentyx 22)
FDA Label Image

Figure F (Cosentyx 23)

Figure F (Cosentyx 23)
FDA Label Image

Figure G (Cosentyx 24)

Figure G (Cosentyx 24)
FDA Label Image

Figure H (Cosentyx 25)

Figure H (Cosentyx 25)
FDA Label Image

Holding Your Cosentyx Sensoready Pen: (Cosentyx 26)

Holding Your Cosentyx Sensoready Pen: (Cosentyx 26)
FDA Label Image

Figure I (Cosentyx 27)

Figure I (Cosentyx 27)
FDA Label Image

Figure J (Cosentyx 28)

Figure J (Cosentyx 28)
FDA Label Image

Figure K (Cosentyx 29)

Figure K (Cosentyx 29)
FDA Label Image

Figure L (Cosentyx 30)

Figure L (Cosentyx 30)
FDA Label Image

Figure M (Cosentyx 31)

Figure M (Cosentyx 31)
FDA Label Image

Figure 4: Asas40 Responses In Nr-axspa1 Study Over Time Up To Week 16 (Cosentyx 32)

Figure 4: Asas40 Responses In Nr-axspa1 Study Over Time Up To Week 16 (Cosentyx 32)
The text shows a graph of the percentage of responders over time (in weeks) for three different treatments: Cosentyx 150 mg Load, Cosentyx 150 mg No Load, and Placebo. The graph shows that both Cosentyx treatments have a higher percentage of responders than the Placebo, and that the Load treatment appears to have a quicker and more significant effect than the No Load. No further information is available.*
FDA Label Image

Principal Display Panel Ndc 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Attention: Dispense With Enclosed Medication Guide. Novartis (Cosentyx 33)

Principal Display Panel Ndc 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Attention: Dispense With Enclosed Medication Guide. Novartis (Cosentyx 33)
Cosentyx is an injectable medication for subcutaneous use for the treatment of plaque psoriasis. The medication significantly reduces inflammation, slows down joint damage, and improves symptoms associated with psoriasis. It is important to store this medication at a temperature between 2°C to 8°C and to discard the unused portion. The drug contains natural rubber latex which may cause an allergic reaction. Patient instructions and drug information are provided.*
FDA Label Image

Figure 1: Percent Of Patients Achieving Acr 20 Responsea In Psa1 Study Through Week 24 (Cosentyx 34)

Figure 1: Percent Of Patients Achieving Acr 20 Responsea In Psa1 Study Through Week 24 (Cosentyx 34)
This text appears to be a chart or graph displaying the percentage of respondents, time in weeks, and treatment options (10mg Cosenly, Cosentyx 0mg, and placebo). It is not possible to determine the context or purpose of the chart from this limited information.*
FDA Label Image

Figure 2: Asas20 Responses In All As1 Study Patients Over Time Up To Week 16 (Cosentyx 35)

Figure 2: Asas20 Responses In All As1 Study Patients Over Time Up To Week 16 (Cosentyx 35)
This appears to be a graph or chart showing the percentage of respondents in relation to weeks and treatment (Cosentyx 150mg and Placebo). Without further context, it is not possible to provide a more detailed or accurate description.*
FDA Label Image

Figure 3: Asas20 Responses In All As3 Study Patients Over Time Up To Week 16 (Cosentyx 36)

Figure 3: Asas20 Responses In All As3 Study Patients Over Time Up To Week 16 (Cosentyx 36)
This appears to be a graph showing the percentage of respondents over time in weeks for different treatments, including Cosenlyx at 150 mg with IV loading and Coseniyx at 300 mg with IV loading, compared to a placebo. The graph shows that both doses of Cosenlyx have a higher percentage of respondents than the placebo.*
FDA Label Image

Cosentyx Prefilled Syringe Parts (see Figure A): (Cosentyx 37)

Cosentyx Prefilled Syringe Parts (see Figure A): (Cosentyx 37)
This appears to be a description of a syringe. It includes features such as finger grips, a plunger, a view window, a needle cap, label and guard wings, and an expiration date label.*
FDA Label Image

Figure B (Cosentyx 38)

Figure B (Cosentyx 38)
FDA Label Image

Figure C (Cosentyx 39)

Figure C (Cosentyx 39)
FDA Label Image

Figure D (Cosentyx 40)

Figure D (Cosentyx 40)
FDA Label Image

Figure E (Cosentyx 41)

Figure E (Cosentyx 41)
FDA Label Image

Figure F (Cosentyx 42)

Figure F (Cosentyx 42)
FDA Label Image

Figure G (Cosentyx 43)

Figure G (Cosentyx 43)
FDA Label Image

Figure H (Cosentyx 44)

Figure H (Cosentyx 44)
FDA Label Image

Figure I (Cosentyx 45)

Figure I (Cosentyx 45)
FDA Label Image

Figure J (Cosentyx 46)

Figure J (Cosentyx 46)
FDA Label Image

Cosentyx 47

Cosentyx 47
FDA Label Image

Cosentyx 48

Cosentyx 48
This data appears to be from a clinical trial comparing the effectiveness of a drug called Cosentyx with a placebo. The x-axis displays time in days, while the y-axis shows the number of patients at risk. The numbers below the x-axis, however, are not legible or recognizable, so it is not possible to provide further information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.